Drug intelligence / Profile preview

KR-505

Development stage: Preclinical
Lead developer: Kernal Biologics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
Administration: Parenteral

Overview

KR-505 is an investigational mRNA-based therapeutic developed by Kernal Biologics, utilizing the company's proprietary mRNA 2.0 platform. It is being researched as a potential treatment for solid tumors. The precise mechanism of action has not been publicly defined, but it falls under the categories of antineoplastics, immunotherapies, and RNA therapeutics. As of early 2025, development remains in the research phase with no orphan drug designation and no reported clinical trial phases[1].

Beyond the preview

Go deeper on KR-505.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KR-505.

Explore the full profile